Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
15 déc. 2022 07h00 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
01 déc. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
10 nov. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
08 nov. 2022 16h05 HE
|
Lyell Immunopharma, Inc
Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical developmentCash, cash equivalents and marketable securities of $750.7...
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
07 nov. 2022 08h05 HE
|
Lyell Immunopharma, Inc
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO,...
Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference
02 nov. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
06 oct. 2022 16h05 HE
|
Lyell Immunopharma, Inc
Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
05 oct. 2022 08h05 HE
|
Lyell Immunopharma, Inc
Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyell’s next product candidate SOUTH SAN FRANCISCO, Calif., Oct. ...
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer
28 sept. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...